HCM — HUTCHMED (China) Share News

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Market Cap
£1.92bn
Enterprise Value
£1.39bn
Revenue
$630.20m

REG - Hutchmed China Ltd - Vesting of awards under the LTIP
05/03/2024 08:30Announcement
RCS - Hutchmed China Ltd - Publication of Form 20-F
28/02/2024 12:45Announcement
REG - Hutchmed China Ltd - 2023 Full Year Results and Business Updates
28/02/2024 11:30Announcement
RCS - Hutchmed China Ltd - Presentation of Phase III Data on Fruquintinib
07/02/2024 07:00Announcement
RCS - Hutchmed China Ltd - Inmagene Exercises Option for Two Drug Candidates
02/02/2024 08:45Announcement
REG - Hutchmed China Ltd - HUTCHMED to Announce 2023 Final Results
01/02/2024 08:30Announcement
RCS - Hutchmed China Ltd - HUTCHMED Receives Marketing Approval in Hong Kong
30/01/2024 07:15Announcement
RCS - Hutchmed China Ltd - Sovleplenib NDA Granted Priority Review in China
11/01/2024 07:00Announcement
REG - Hutchmed China Ltd - Total Voting Rights
29/12/2023 08:30Announcement
REG - Hutchmed China Ltd - Blocklisting Six Monthly Return
29/12/2023 08:30Announcement
REG - Hutchmed China Ltd - Overseas Regulatory Announcement
21/12/2023 10:00Announcement
RCS - Hutchmed China Ltd - Completed Enrollment of Phase II/III Trial
13/12/2023 07:15Announcement
RCS - Hutchmed China Ltd - Inclusion in National Reimbursement Drug List
13/12/2023 07:15Announcement
REG - Hutchmed China Ltd - Overseas Regulatory Announcement
07/12/2023 10:15Announcement
RCS - Hutchmed China Ltd - Clinical Data to be Presented at Congresses
01/12/2023 07:00Announcement
REG - Hutchmed China Ltd - Total Voting Rights
30/11/2023 08:30Announcement
REG - Hutchmed China Ltd - U.S. FDA Approval of FRUZAQLA™ (fruquintinib)
09/11/2023 07:15Announcement
REG - Hutchmed China Ltd - Vesting of awards under the LTIP
24/10/2023 09:30Announcement
RCS - Hutchmed China Ltd - Clinical Data to be Presented at ESMO 2023
16/10/2023 09:30Announcement
REG - Hutchmed China Ltd - Total Voting Rights
29/09/2023 09:30Announcement